Caladrius Biosciences Inc (CLBS)

Sector:
FINANCE
Industry:
INSURANCE
SIC:
SERVICES-MISC HEALTH & ALLIED SERVICES, NEC
CEO:
David J. Mazzo
Employees:
25
110 ALLEN ROAD, SECOND FLOOR, BASKING RIDGE, NJ 07920
908-842-0100

Caladrius Biosciences, Inc. operates as a global healthcare company, which engages in developing cellular therapies that repair damaged tissue, cells and organs and restore their normal function. It is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease. Its business includes the development of novel proprietary cell therapy products, as well as a revenue-generating contract development and manufacturing service business that it leverages for the development of therapeutics while providing service to other companies in the cell therapy industry developing products. The company was founded in September 1980 and is headquartered in New York, NY.

Data derived from most recent annual or quarterly report
Market Cap 26.781 Million Shares Outstanding59.78 Million Avg 30-day Volume 799.229 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.29
Price to Revenue0.0 Debt to Equity0.0 EBITDA-26.556 Million
Price to Book Value0.5046 Operating Margin0.0 Enterprise Value-48.673 Million
Current Ratio21.265 EPS Growth0.057 Quick Ratio20.997
1 Yr BETA 0.9918 52-week High/Low 1.68 / 0.4 Profit Margin0.0
Operating Cash Flow Growth-152.1251 Altman Z-Score-0.8175 Free Cash Flow to Firm -19.696 Million
Earnings Report2022-08-04
View SEC Filings from CLBS instead.

View recent insider trading info

Funds Holding CLBS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CLBS BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

MAZZO DAVID J CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
631,065 2022-01-13 2

GIROLAMO TODD C CLO, SVP OF CORP DEV

  • Officer
160,827 2022-01-13 3

MYERS STEVEN S

  • Director
223,459 2022-01-10 2

KLOSK STEVEN M

  • Director
151,390 2022-01-10 1

TRABER PETER G

  • Director
149,190 2022-01-10 1

BROWN GREGORY B

  • Director
149,040 2022-01-10 1

DAVIDSON MICHAEL H.

  • Director
209,753 2022-01-10 1

WHITAKER ANNE CLEM

  • Director
182,635 2022-01-10 1

FLOWERS CYNTHIA LOUISE

  • Director
145,847 2022-01-10 1

BUCK KRISTEN K EVP, R&D AND CMO

  • Officer
351,703 2022-01-10 1

TALAMO JOSEPH SVP AND CFO

  • Officer
59,644 2020-01-13 0

LOSORDO DOUGLAS W SEE REMARKS

  • Officer
130,406 2020-01-13 0

PRETI ROBERT A

  • SEE REMARKS
No longer subject to file 2017-05-18 0

SANFORD

SANFORD HEALTH

  • 10% Owner
1,059,322 2017-03-22 0

WEI ERIC

  • Director
176,523 2017-02-07 0

BERMAN RICHARD J

  • Director
7,177 2017-01-09 0

NEWHALL CONSTRUCTION LTD.

  • 10% Owner
1,271,186 2016-09-14 0

PECORA ANDREW L

  • Director
393,784 2016-06-22 0

VATERS ROBERT S PRESIDENT & CFO

  • Officer
  • Director
228,750 2015-08-12 0

GREENACRE MARTYN D

  • Director
88,531 2015-06-02 0

SMITH ROBIN L EXECUTIVE CHAIR OF THE BOARD

  • Officer
  • Director
347,285 2015-06-02 0

BERNSTEIN DREW

  • Director
10,000 2015-06-02 0

VACZY CATHERINE M GENERAL COUNSEL

  • Officer
71,234 2015-04-13 0

RIMASIA CAPITAL PARTNERS MANAGER, LTD.

RIMASIA CAPITAL PARTNERS, L.P.

RIMASIA CAPITAL PARTNERS GP, L.P.

RIMASIA CAPITAL PARTNERS GP, LTD.

WEI ERIC

  • Director
  • 10% Owner
2,222,988 2015-01-02 0

DICKEY ROBERT IV CHIEF FINANCIAL OFFICER

  • Officer
12,066 2014-12-31 0

POTTER STEPHEN W EXECUTIVE VICE PRESIDENT

  • Officer
14,016 2014-12-31 0

KEIRSTEAD HANS SEE REMARKS

  • Officer
0 2014-05-09 0

DILLMAN ROBERT SEE REMARKS

  • Officer
0 2014-05-09 0

MAY LARRY ALAN CHIEF FINANCIAL OFFICER

  • Officer
0 2013-01-02 0

RIMASIA CAPITAL PARTNERS MANAGER, LTD.

  • 10% Owner
22,515,180 2012-09-17 0

GEEHR EDWARD

  • Director
0 2012-06-29 0

SCHMIEG MARTIN E VICE PRESIDENT- CORPORATE DEV

  • Officer
0 2012-06-25 0

SACKNER-BERNSTEIN JONATHAN VP CLINICAL DEV & REG AFFAIRS

  • Officer
0 2012-04-02 0

RIMASIA CAPITAL PARTNERS, L.P.

RIMASIA CAPITAL PARTNERS GP, L.P.

RIMASIA CAPITAL PARTNERS GP, LTD.

WEI ERIC

  • Director
  • 10% Owner
22,529,874 2012-01-12 0

SHI MINGSHENG SEE REMARKS

  • Officer
  • Director
0 2012-01-04 0

KOLBERT JASON SEE REMARKS

  • Officer
0 2012-01-04 0

HARRIS ALAN G SEE REMARKS

  • Officer
0 2011-04-04 0

ZHANG IAN SEE REMARKS

  • Officer
0 2011-04-04 0

ZHANG JIAN M SEE REMARKS

  • Officer
0 2010-06-09 0

SALERNO ANTHONY SEE REMARKS

  • Officer
0 2010-06-09 0

FULLBRIGHT FINANCE LTD

  • 10% Owner
3,047,432 2009-12-30 0

DUIGNAN CHRISTOPHER C VICE PRESIDENT, FINANCE

  • Officer
0 2009-11-30 0

SAMUELS LEPORE TERESA LINN VP OF SALES AND MARKETING

  • Officer
0 2009-10-29 0

SOUTHPOINT CAPITAL ADVISORS LP

SOUTHPOINT GP, LP

SOUTHPOINT CAPITAL ADVISORS LLC

SOUTHPOINT GP, LLC

BUTTS ROBERT W

CLARK JOHN SMITH II

  • 10% Owner
No longer subject to file 2009-06-18 0

WEINREB MARK PRESIDENT

  • Officer
0 2009-05-21 0

ZUCKERMAN JOSEPH

  • Director
0 2009-05-21 0

ENHANCE BIOMEDICAL HOLDINGS LTD

  • 10% Owner
4,000,000 2009-04-09 0

MARGULA CO LLC

  • CONSULTANT
0 2008-12-31 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
CALADRIUS BIOSCIENCES INC CLBS 2022-05-17 22:15:04 UTC -2.5167 3.3367 1100000
CALADRIUS BIOSCIENCES INC CLBS 2022-05-17 21:45:04 UTC -2.5167 3.3367 1100000
CALADRIUS BIOSCIENCES INC CLBS 2022-05-17 21:15:03 UTC -2.5167 3.3367 1100000
CALADRIUS BIOSCIENCES INC CLBS 2022-05-17 20:45:03 UTC -2.5167 3.3367 1100000
CALADRIUS BIOSCIENCES INC CLBS 2022-05-17 20:15:05 UTC -2.5167 3.3367 1100000
CALADRIUS BIOSCIENCES INC CLBS 2022-05-17 19:45:04 UTC -2.5167 3.3367 1100000
CALADRIUS BIOSCIENCES INC CLBS 2022-05-17 19:15:03 UTC -2.5167 3.3367 1100000
CALADRIUS BIOSCIENCES INC CLBS 2022-05-17 18:45:03 UTC -2.5167 3.3367 1100000
CALADRIUS BIOSCIENCES INC CLBS 2022-05-17 18:15:03 UTC -2.5167 3.3367 1100000
CALADRIUS BIOSCIENCES INC CLBS 2022-05-17 17:45:03 UTC -2.5167 3.3367 1100000
CALADRIUS BIOSCIENCES INC CLBS 2022-05-17 17:15:03 UTC -2.5167 3.3367 1100000
CALADRIUS BIOSCIENCES INC CLBS 2022-05-17 16:45:04 UTC -2.5167 3.3367 1100000
CALADRIUS BIOSCIENCES INC CLBS 2022-05-17 16:15:03 UTC -2.5167 3.3367 1100000
CALADRIUS BIOSCIENCES INC CLBS 2022-05-17 15:45:03 UTC -2.5167 3.3367 1100000
CALADRIUS BIOSCIENCES INC CLBS 2022-05-17 15:15:03 UTC -2.5167 3.3367 1100000
CALADRIUS BIOSCIENCES INC CLBS 2022-05-17 14:45:03 UTC -2.5167 3.3367 850000
CALADRIUS BIOSCIENCES INC CLBS 2022-05-17 14:15:03 UTC -2.5167 3.3367 850000
CALADRIUS BIOSCIENCES INC CLBS 2022-05-17 13:45:03 UTC -2.5167 3.3367 850000
CALADRIUS BIOSCIENCES INC CLBS 2022-05-17 13:15:03 UTC -2.5167 3.3367 850000
CALADRIUS BIOSCIENCES INC CLBS 2022-05-17 12:45:03 UTC -2.5167 3.3367 850000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments